PMID- 23108364
OWN - NLM
STAT- MEDLINE
DCOM- 20130919
LR  - 20211021
IS  - 1432-069X (Electronic)
IS  - 0340-3696 (Print)
IS  - 0340-3696 (Linking)
VI  - 305
IP  - 3
DP  - 2013 Apr
TI  - Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum 
      level in psoriatic patients.
PG  - 191-5
LID - 10.1007/s00403-012-1293-6 [doi]
AB  - Scientific communications indicate the disturbed expression of neuropeptides in 
      the skin and serum in psoriasis vulgaris (PsV) patients. Narrow-band ultraviolet 
      radiation (NB-UVB) is one of the systemic therapies of PsV. The aim of the study 
      was to evaluate the influence of NB-UVB therapy on substance P (SP), calcitonin 
      gene-related peptide (CGRP), brain-derived neurotrophic factor (BDNF), 
      corticotropin-releasing factor (CRF) and interleukin-31 (IL-31) serum 
      concentrations in PsV patients. 59 psoriatic patients with mean PASI (psoriasis 
      area and severity index) 14.3 were treated with NB-UVB (20 exposures). The 
      control group consisted of 50 healthy subjects, whose age and sex matched. In all 
      patients, serum concentration of BDNF, CRF, IL-31 substance P and CGRP was 
      analyzed by ELISA before the treatment and in psoriatic group the analysis was 
      also done after 10 and 20 irradiations. In patients there was found a 
      significantly higher concentration of IL-31 (215.3 vs. 748.6 ng/ml; p < 0.0001), 
      SP (25.7 vs. 67.2 pg/ml; p < 0.01), CGRP (31.4 vs. 44.15 pg/ml; p < 0.01) and a 
      lower concentration of CRF (0.89 vs. 0.426 ng/ml; p < 0.0001) and BDNF (16.39 vs. 
      14.15 ng/ml; p = 0.1216) in comparison with the controls. 20 NB-UVB exposures 
      caused a significant decrease in IL-31 level (748.6 vs. 631.7 ng/ml; p < 0.0001). 
      The NB-UVB therapy had no major effect on neuropeptides serum levels regardless 
      of a number of irradiations. On the basis of our study it can be suggested that 
      IL-31 is involved in pathogenesis of psoriasis and the NB-UVB therapy causes 
      alterations in its level.
FAU - Narbutt, Joanna
AU  - Narbutt J
AD  - Department of Dermatology, Medical University of Lodz, 5 Krzemieniecka, 94-017, 
      Lodz, Poland. joanna.narbutt@umed.lodz.pl
FAU - Olejniczak, Irmina
AU  - Olejniczak I
FAU - Sobolewska-Sztychny, Dorota
AU  - Sobolewska-Sztychny D
FAU - Sysa-Jedrzejowska, Anna
AU  - Sysa-Jedrzejowska A
FAU - Slowik-Kwiatkowska, Iwona
AU  - Slowik-Kwiatkowska I
FAU - Hawro, Tomasz
AU  - Hawro T
FAU - Lesiak, Aleksandra
AU  - Lesiak A
LA  - eng
PT  - Journal Article
DEP - 20121030
PL  - Germany
TA  - Arch Dermatol Res
JT  - Archives of dermatological research
JID - 8000462
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (IL31 protein, human)
RN  - 0 (Interleukins)
RN  - 33507-63-0 (Substance P)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - 9015-71-8 (Corticotropin-Releasing Hormone)
RN  - JHB2QIZ69Z (Calcitonin Gene-Related Peptide)
SB  - IM
MH  - Adult
MH  - Brain-Derived Neurotrophic Factor/blood
MH  - Calcitonin Gene-Related Peptide/blood
MH  - Corticotropin-Releasing Hormone/blood
MH  - Female
MH  - Humans
MH  - Interleukins/*blood
MH  - Male
MH  - Middle Aged
MH  - Pruritus/blood/*radiotherapy
MH  - Psoriasis/blood/*radiotherapy
MH  - Skin/radiation effects
MH  - Substance P/blood
MH  - Surveys and Questionnaires
MH  - Ultraviolet Rays
MH  - *Ultraviolet Therapy
PMC - PMC3606511
EDAT- 2012/10/31 06:00
MHDA- 2013/09/21 06:00
PMCR- 2012/10/30
CRDT- 2012/10/31 06:00
PHST- 2012/07/19 00:00 [received]
PHST- 2012/10/09 00:00 [accepted]
PHST- 2012/09/30 00:00 [revised]
PHST- 2012/10/31 06:00 [entrez]
PHST- 2012/10/31 06:00 [pubmed]
PHST- 2013/09/21 06:00 [medline]
PHST- 2012/10/30 00:00 [pmc-release]
AID - 1293 [pii]
AID - 10.1007/s00403-012-1293-6 [doi]
PST - ppublish
SO  - Arch Dermatol Res. 2013 Apr;305(3):191-5. doi: 10.1007/s00403-012-1293-6. Epub 
      2012 Oct 30.